Certainty assessment | No. of patients | Effect | Certainty | Importance | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | SGLT2i | Control | Relative (95% CI) | Absolute (95% CI) | ||
LVMI | ||||||||||||
6 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 251 | 254 | – | MD 0.96 lower (2.69 lower to 0.77 higher) | ⨁⨁⨁◯ Moderate | Important |
LVEDVI | ||||||||||||
3 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 89 | 93 | – | MD 1.32 higher (2.20 lower to 4.85 higher) | ⨁⨁⨁◯ Moderate | Important |
LVESVI | ||||||||||||
3 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 89 | 93 | – | MD 0.03 lower (3.08 lower to 3.02 higher) | ⨁⨁⨁◯ Moderate | Important |
LAVI | ||||||||||||
4 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 187 | 182 | – | MD 0.28 lower (1.98 lower to 1.42 higher) | ⨁⨁⨁◯ Moderate | Important |
LVEF | ||||||||||||
9 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 427 | 442 | - | MD 0.21 higher (0.65 lower to 1.06 higher) | ⨁⨁⨁◯ Moderate | Important |
LVEF in HFrEF | ||||||||||||
2 | Randomized trials | Serious b | Not serious | Not serious | Seriousa | None | 70 | 74 | – | MD 3.16 higher (0.11 higher to 6.22 higher) | ⨁⨁◯◯ Low | Important |
LVEF in HFpEF | ||||||||||||
2 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 151 | 158 | – | MD 0.19 higher (1.76 lower to 2.15 higher) | ⨁⨁⨁◯ Moderate | Important |
GLS | ||||||||||||
4 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 162 | 164 | – | MD 0.38 lower (1.04 lower to 0.29 higher) | ⨁⨁⨁◯ Moderate | Important |
E/eʹ | ||||||||||||
8 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 354 | 371 | – | MD 0.45 lower (0.88 lower to 0.03 lower) | ⨁⨁⨁◯ Moderate | Important |
NT-proBNP | ||||||||||||
11 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 1997 | 1777 | – | SMD 0.09 lower (0.16 lower to 0.03 lower) | ⨁⨁⨁◯ Moderate | Critical |
NT-proBNP (ln scale) | ||||||||||||
3 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 2702 | 1629 | – | SMD 0.12 lower (0.17 lower to 0.07 lower) | ⨁⨁⨁◯ Moderate | Critical |
KCCQ | ||||||||||||
3 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None | 2610 | 2607 | – | SMD 3.12 higher (0.76 higher to 5.47 higher) | ⨁⨁⨁⨁ High | Critical |